Michael Mason Sells 36,745 Shares of Alnylam Pharmaceuticals, Inc. (ALNY) Stock
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the transaction, the vice president now owns 6,352 shares of the company’s stock, valued at approximately $835,859.68. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at $130.74 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $35.98 and a 12-month high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. The company has a market capitalization of $12,860.00, a PE ratio of -24.90 and a beta of 2.98.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same quarter last year, the business earned ($1.21) earnings per share. Alnylam Pharmaceuticals’s revenue was up 24.8% on a year-over-year basis. analysts predict that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current fiscal year.
ALNY has been the subject of a number of research analyst reports. Jefferies Group raised their target price on Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, September 26th. Chardan Capital reiterated a “buy” rating and set a $124.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, September 25th. Needham & Company LLC lifted their price objective on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, September 20th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $146.00 price objective (up previously from $90.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 21st. Finally, Sanford C. Bernstein reiterated a “buy” rating and set a $135.00 price objective (up previously from $94.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 21st. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $121.20.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.